This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Karbowniczek, M. Articles by Henske, E. P. Search for Related Content PubMed PubMed Citation Articles by Karbowniczek, M. Articles by Henske, E. P.

(American Journal of Pathology. 2003;162:491-500.)
© 2003 American Society for Investigative Pathology

Regular Articles

Renal Angiomyolipomas from Patients with Sporadic Lymphangiomyomatosis Contain Both Neoplastic and Non-Neoplastic Vascular Structures

From the Fox Chase Cancer Center, Philadelphia, Pennsylvania

Renal angiomyolipomas are highly vascular tumors that occur sporadically, in women with pulmonary lymphangiomyomatosis (LAM), and in tuberous sclerosis complex (TSC). The goal of this study was to determine whether the distinctive vessels of angiomyolipomas are neoplastic or reactive. We studied angiomyolipomas with loss of heterozygosity (LOH) in the TSC2 region of chromosome 16p13 from patients with LAM. We found that angiomyolipomas contain five morphologically distinct vessel types: cellular, collagenous, hemangiopericytic, glomeruloid, and aneurysmatic. Using laser capture microdissection, we determined that four of the vessel types have TSC2 LOH and are therefore neoplastic. One vessel type, collagenous vessels, did not have LOH, and is presumably reactive. Recently, activation of S6 Kinase and its target S6 ribosomal protein (S6) was demonstrated in cells lacking TSC2 expression. We found that angiomyolipoma vessel types in which LOH were detected were immunoreactive with anti-phospho-S6 antibodies. Angiomyolipoma cells without LOH, including the endothelial component of the vessels, were not immunoreactive. To our knowledge, angiomyolipomas are the first benign vascular tumor in which the vascular cells, rather than the stromal cells, have been found to be neoplastic. Angiomyolipomas appear to reflect novel vascular mechanisms that may be the result of activation of cellular pathways involving S6 Kinase.

This article has been cited by other articles:

				S. Li, F. Takeuchi, J.-a. Wang, Q. Fan, T. Komurasaki, E. M. Billings, G. Pacheco-Rodriguez, J. Moss, and T. N. Darling Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas PNAS, March 4, 2008; 105(9): 3539 - 3544. [Abstract] [Full Text] [PDF]

				F. X. McCormack Lymphangioleiomyomatosis: A Clinical Update Chest, February 1, 2008; 133(2): 507 - 516. [Abstract] [Full Text] [PDF]

				G. Pacheco-Rodriguez, W. K. Steagall, D. M. Crooks, L. A. Stevens, H. Hashimoto, S. Li, J.-a. Wang, T. N. Darling, and J. Moss TSC2 Loss in Lymphangioleiomyomatosis Cells Correlated with Expression of CD44v6, a Molecular Determinant of Metastasis Cancer Res., November 1, 2007; 67(21): 10573 - 10581. [Abstract] [Full Text] [PDF]

				A. M. Taveira-DaSilva, O. M. Hathaway, V. Sachdev, Y. Shizukuda, C. W. Birdsall, and J. Moss Pulmonary Artery Pressure in Lymphangioleiomyomatosis: An Echocardiographic Study Chest, November 1, 2007; 132(5): 1573 - 1578. [Abstract] [Full Text] [PDF]

				M. Karbowniczek, G. P. Robertson, and E. P. Henske Rheb Inhibits C-Raf Activity and B-Raf/C-Raf Heterodimerization J. Biol. Chem., September 1, 2006; 281(35): 25447 - 25456. [Abstract] [Full Text] [PDF]

				S. R. Johnson Lymphangioleiomyomatosis. Eur. Respir. J., May 1, 2006; 27(5): 1056 - 1065. [Abstract] [Full Text] [PDF]

				M. KARBOWNICZEK and E. P. HENSKE The Role of Tuberin in Cellular Differentiation: Are B-Raf and MAPK Involved? Ann. N.Y. Acad. Sci., November 1, 2005; 1059(1): 168 - 173. [Abstract] [Full Text] [PDF]

				E. Lesma, V. Grande, S. Carelli, D. Brancaccio, M. P. Canevini, R. M. Alfano, G. Coggi, A. M. Di Giulio, and A. Gorio Isolation and Growth of Smooth Muscle-Like Cells Derived from Tuberous Sclerosis Complex-2 Human Renal Angiomyolipoma: Epidermal Growth Factor Is the Required Growth Factor Am. J. Pathol., October 1, 2005; 167(4): 1093 - 1103. [Abstract] [Full Text] [PDF]

				L. Meikle, J. R. McMullen, M. C. Sherwood, A. S. Lader, V. Walker, J. A. Chan, and D. J. Kwiatkowski A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes Hum. Mol. Genet., February 1, 2005; 14(3): 429 - 435. [Abstract] [Full Text] [PDF]

				D. M. Crooks, G. Pacheco-Rodriguez, R. M. DeCastro, J. P. McCoy Jr., J.-a. Wang, F. Kumaki, T. Darling, and J. Moss Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis PNAS, December 14, 2004; 101(50): 17462 - 17467. [Abstract] [Full Text] [PDF]

				A. Astrinidis and E. Petri Henske Aberrant Cellular Differentiation and Migration in Renal and Pulmonary Tuberous Sclerosis Complex J Child Neurol, September 1, 2004; 19(9): 710 - 715. [Abstract] [PDF]

				J. A. Whitsett, C. J. Bachurski, K. C. Barnes, P. A. Bunn Jr., L. M. Case, D. N. Cook, D. Crooks, M. W. Duncan, L. Dwyer-Nield, R. C. Elston, et al. Functional Genomics of Lung Disease Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2/S1): S1 - S81. [Full Text] [PDF]

				L. S. Harrington, G. M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N. R. Leslie, S. Cheng, P. R. Shepherd, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J. Cell Biol., July 19, 2004; 166(2): 213 - 223. [Abstract] [Full Text] [PDF]

				M. Karbowniczek, T. Cash, M. Cheung, G. P. Robertson, A. Astrinidis, and E. P. Henske Regulation of B-Raf Kinase Activity by Tuberin and Rheb Is Mammalian Target of Rapamycin (mTOR)-independent J. Biol. Chem., July 16, 2004; 279(29): 29930 - 29937. [Abstract] [Full Text] [PDF]

				N. El-Hashemite, H. Zhang, V. Walker, K. M. Hoffmeister, and D. J. Kwiatkowski Perturbed IFN-{gamma}-Jak-Signal Transducers and Activators of Transcription Signaling in Tuberous Sclerosis Mouse Models: Synergistic Effects of Rapamycin-IFN-{gamma} Treatment Cancer Res., May 15, 2004; 64(10): 3436 - 3443. [Abstract] [Full Text] [PDF]

				G. Finlay The LAM cell: what is it, where does it come from, and why does it grow? Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L690 - L693. [Full Text] [PDF]

				J. Yu, A. Astrinidis, S. Howard, and E. P. Henske Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L694 - L700. [Abstract] [Full Text] [PDF]

				A. Astrinidis, W. Senapedis, T. R. Coleman, and E. P. Henske Cell Cycle-regulated Phosphorylation of Hamartin, the Product of the Tuberous Sclerosis Complex 1 Gene, by Cyclin-dependent Kinase 1/Cyclin B J. Biol. Chem., December 19, 2003; 278(51): 51372 - 51379. [Abstract] [Full Text] [PDF]